schliessen

Filtern

 

Bibliotheken

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)

Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal o... Full description

Journal Title: The American heart journal 2012, Vol.163 (1), p.13-19.e1
Main Author: Kakkar, Ajay K., MBBS, PhD
Other Authors: Mueller, Iris, MD , Bassand, Jean-Pierre, MD , Fitzmaurice, David A., MD , Goldhaber, Samuel Z., MD , Goto, Shinya, MD, PhD , Haas, Sylvia, MD , Hacke, Werner, MD , Lip, Gregory Y.H., MD , Mantovani, Lorenzo G., MD , Verheugt, Freek W.A., MD , Jamal, Waheed, MD , Misselwitz, Frank, MD, PhD , Rushton-Smith, Sophie, PhD , Turpie, Alexander G.G., MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-8703
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_911950684
title: International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
format: Article
creator:
  • Kakkar, Ajay K., MBBS, PhD
  • Mueller, Iris, MD
  • Bassand, Jean-Pierre, MD
  • Fitzmaurice, David A., MD
  • Goldhaber, Samuel Z., MD
  • Goto, Shinya, MD, PhD
  • Haas, Sylvia, MD
  • Hacke, Werner, MD
  • Lip, Gregory Y.H., MD
  • Mantovani, Lorenzo G., MD
  • Verheugt, Freek W.A., MD
  • Jamal, Waheed, MD
  • Misselwitz, Frank, MD, PhD
  • Rushton-Smith, Sophie, PhD
  • Turpie, Alexander G.G., MD
subjects:
  • Abridged Index Medicus
  • Anticoagulants
  • Anticoagulants (Medicine)
  • Anticoagulants - administration & dosage
  • Atrial fibrillation
  • Atrial Fibrillation - complications
  • Atrial Fibrillation - drug therapy
  • Atrial Fibrillation - mortality
  • Biological and medical sciences
  • Blood clots
  • Blood. Blood coagulation. Reticuloendothelial system
  • Cardiac dysrhythmias
  • Cardiology. Vascular system
  • Cardiovascular
  • Clinical medicine
  • Cohort Studies
  • Global Health
  • Heart
  • Humans
  • Longitudinal Studies
  • Medical sciences
  • Multicenter Studies as Topic
  • Neurology
  • Patient Selection
  • Pharmacology. Drug treatments
  • Prospective Studies
  • Recruitment
  • Registries
  • Research Design
  • Risk Factors
  • Stroke
  • Stroke (Disease)
  • Stroke - complications
  • Stroke - drug therapy
  • Stroke - mortality
  • Vascular diseases and vascular malformations of the nervous system
  • Veins & arteries
ispartof: The American heart journal, 2012, Vol.163 (1), p.13-19.e1
description: Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.681992
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_911950684
sourceformatXML
sourcesystemPC
galeidA275140576
sourcerecordidA275140576
originalsourceidFETCH-LOGICAL-1633t-f57f4b7021945e90ab8b69ee6174c68ab651a17a51114a9c30e8d3d0ba9aa56b3
addsrcrecordideNp9k9-LEzEQxxdRvHr6B_giCyLqQ2tmf2Q3JwrlvKsHBeFU8C1ks9le2jSpSVa5P8P_2Nn2zmqRYx9mM3y-M5PMTJI8BTIBAvTNciKulpOMAEwIm6C5l4yAsGpMq6K4n4wIIdm4rkh-lDwKYYlHmtX0YXKUZVBlRQ6j5NeFjcpbEbWzwqTG2YWOfauHg1cLHaK_Tl2XbpBQNob0p45XqYheI9DpxmtjtmL0pV6H1QCjyK3USTozrkFsaqOWTix6I2xML2-japvGK5WeX5zNP6SvZtPL7d_rx8mDTpigntzY4-Tr-dmX04_j-afZxel0Pgaa53HclVVXNBXJgBWlYkQ0dUOZUhSqQtJaNLQEAZUoAaAQTOZE1W3ekkYwIUra5MfJy13cjXffexUiX-sgFV7HKtcHzgBYSWhdIPn8gFy6Ht_MBA4lKWjOGIE9tRBGcW07F72QQ0w-zaoSClJWFKnJfyj8WrXGR7Kq0-j_RwA7gfQuBK86vvF6Lfw1B8KHKeBLjlPAhynghHE0qHl2U3DfrFX7R3HbdgRe3AAiSGE6L6zUYc9h4gy2gaqD5FLHbbuxam3uLOHdTmmF_zu077kTmnu1cUFHh56-sYPXGtRTivHqgmSof7vTKxyBH1p5HiQOoFSt9kpG3jp9Z_b3B2pptNV41ZW6VmHfPh4yTvjnYVGGPQHAFWH0W_4b7y4K-g
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1504639901
display
typearticle
titleInternational longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
sourceAlma/SFX Local Collection
creatorKakkar, Ajay K., MBBS, PhD ; Mueller, Iris, MD ; Bassand, Jean-Pierre, MD ; Fitzmaurice, David A., MD ; Goldhaber, Samuel Z., MD ; Goto, Shinya, MD, PhD ; Haas, Sylvia, MD ; Hacke, Werner, MD ; Lip, Gregory Y.H., MD ; Mantovani, Lorenzo G., MD ; Verheugt, Freek W.A., MD ; Jamal, Waheed, MD ; Misselwitz, Frank, MD, PhD ; Rushton-Smith, Sophie, PhD ; Turpie, Alexander G.G., MD
creatorcontribKakkar, Ajay K., MBBS, PhD ; Mueller, Iris, MD ; Bassand, Jean-Pierre, MD ; Fitzmaurice, David A., MD ; Goldhaber, Samuel Z., MD ; Goto, Shinya, MD, PhD ; Haas, Sylvia, MD ; Hacke, Werner, MD ; Lip, Gregory Y.H., MD ; Mantovani, Lorenzo G., MD ; Verheugt, Freek W.A., MD ; Jamal, Waheed, MD ; Misselwitz, Frank, MD, PhD ; Rushton-Smith, Sophie, PhD ; Turpie, Alexander G.G., MD
descriptionBackground Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2011.09.011
3PMID: 22172431
4CODEN: AHJOA2
languageeng
publisherNew York, NY: Elsevier Inc
subjectAbridged Index Medicus ; Anticoagulants ; Anticoagulants (Medicine) ; Anticoagulants - administration & dosage ; Atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - mortality ; Biological and medical sciences ; Blood clots ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiac dysrhythmias ; Cardiology. Vascular system ; Cardiovascular ; Clinical medicine ; Cohort Studies ; Global Health ; Heart ; Humans ; Longitudinal Studies ; Medical sciences ; Multicenter Studies as Topic ; Neurology ; Patient Selection ; Pharmacology. Drug treatments ; Prospective Studies ; Recruitment ; Registries ; Research Design ; Risk Factors ; Stroke ; Stroke (Disease) ; Stroke - complications ; Stroke - drug therapy ; Stroke - mortality ; Vascular diseases and vascular malformations of the nervous system ; Veins & arteries
ispartofThe American heart journal, 2012, Vol.163 (1), p.13-19.e1
rights
0Mosby, Inc.
12012 Mosby, Inc.
2info:eu-repo/semantics/closedAccess
32015 INIST-CNRS
4Copyright © 2012 Mosby, Inc. All rights reserved.
5COPYRIGHT 2012 Elsevier B.V.
6Copyright Elsevier Limited Jan 2012
lds50peer_reviewed
citedbyFETCH-LOGICAL-1633t-f57f4b7021945e90ab8b69ee6174c68ab651a17a51114a9c30e8d3d0ba9aa56b3
citesFETCH-LOGICAL-1633t-f57f4b7021945e90ab8b69ee6174c68ab651a17a51114a9c30e8d3d0ba9aa56b3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25762111$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22172431$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Kakkar, Ajay K., MBBS, PhD
1Mueller, Iris, MD
2Bassand, Jean-Pierre, MD
3Fitzmaurice, David A., MD
4Goldhaber, Samuel Z., MD
5Goto, Shinya, MD, PhD
6Haas, Sylvia, MD
7Hacke, Werner, MD
8Lip, Gregory Y.H., MD
9Mantovani, Lorenzo G., MD
10Verheugt, Freek W.A., MD
11Jamal, Waheed, MD
12Misselwitz, Frank, MD, PhD
13Rushton-Smith, Sophie, PhD
14Turpie, Alexander G.G., MD
title
0International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
1The American heart journal
addtitleAm Heart J
descriptionBackground Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
subject
0Abridged Index Medicus
1Anticoagulants
2Anticoagulants (Medicine)
3Anticoagulants - administration & dosage
4Atrial fibrillation
5Atrial Fibrillation - complications
6Atrial Fibrillation - drug therapy
7Atrial Fibrillation - mortality
8Biological and medical sciences
9Blood clots
10Blood. Blood coagulation. Reticuloendothelial system
11Cardiac dysrhythmias
12Cardiology. Vascular system
13Cardiovascular
14Clinical medicine
15Cohort Studies
16Global Health
17Heart
18Humans
19Longitudinal Studies
20Medical sciences
21Multicenter Studies as Topic
22Neurology
23Patient Selection
24Pharmacology. Drug treatments
25Prospective Studies
26Recruitment
27Registries
28Research Design
29Risk Factors
30Stroke
31Stroke (Disease)
32Stroke - complications
33Stroke - drug therapy
34Stroke - mortality
35Vascular diseases and vascular malformations of the nervous system
36Veins & arteries
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2012
recordtypearticle
recordideNp9k9-LEzEQxxdRvHr6B_giCyLqQ2tmf2Q3JwrlvKsHBeFU8C1ks9le2jSpSVa5P8P_2Nn2zmqRYx9mM3y-M5PMTJI8BTIBAvTNciKulpOMAEwIm6C5l4yAsGpMq6K4n4wIIdm4rkh-lDwKYYlHmtX0YXKUZVBlRQ6j5NeFjcpbEbWzwqTG2YWOfauHg1cLHaK_Tl2XbpBQNob0p45XqYheI9DpxmtjtmL0pV6H1QCjyK3USTozrkFsaqOWTix6I2xML2-japvGK5WeX5zNP6SvZtPL7d_rx8mDTpigntzY4-Tr-dmX04_j-afZxel0Pgaa53HclVVXNBXJgBWlYkQ0dUOZUhSqQtJaNLQEAZUoAaAQTOZE1W3ekkYwIUra5MfJy13cjXffexUiX-sgFV7HKtcHzgBYSWhdIPn8gFy6Ht_MBA4lKWjOGIE9tRBGcW07F72QQ0w-zaoSClJWFKnJfyj8WrXGR7Kq0-j_RwA7gfQuBK86vvF6Lfw1B8KHKeBLjlPAhynghHE0qHl2U3DfrFX7R3HbdgRe3AAiSGE6L6zUYc9h4gy2gaqD5FLHbbuxam3uLOHdTmmF_zu077kTmnu1cUFHh56-sYPXGtRTivHqgmSof7vTKxyBH1p5HiQOoFSt9kpG3jp9Z_b3B2pptNV41ZW6VmHfPh4yTvjnYVGGPQHAFWH0W_4b7y4K-g
startdate2012
enddate2012
creator
0Kakkar, Ajay K., MBBS, PhD
1Mueller, Iris, MD
2Bassand, Jean-Pierre, MD
3Fitzmaurice, David A., MD
4Goldhaber, Samuel Z., MD
5Goto, Shinya, MD, PhD
6Haas, Sylvia, MD
7Hacke, Werner, MD
8Lip, Gregory Y.H., MD
9Mantovani, Lorenzo G., MD
10Verheugt, Freek W.A., MD
11Jamal, Waheed, MD
12Misselwitz, Frank, MD, PhD
13Rushton-Smith, Sophie, PhD
14Turpie, Alexander G.G., MD
general
0Elsevier Inc
1Mosby
2Elsevier B.V
3Elsevier Limited
scope
05DI
15DJ
2QVL
3IQODW
4CGR
5CUY
6CVF
7ECM
8EIF
9NPM
10AAYXX
11CITATION
12BSHEE
133V.
147QO
157RV
167TS
177X7
187XB
1988C
2088E
218AO
228C1
238FD
248FI
258FJ
268FK
278G5
28ABUWG
29AN0
30AZQEC
31BENPR
32DWQXO
33FR3
34FYUFA
35GHDGH
36GNUQQ
37GUQSH
38K9.
39KB0
40M0S
41M0T
42M1P
43M2O
44MBDVC
45NAPCQ
46P64
47PADUT
48PQEST
49PQQKQ
50PQUKI
51PRINS
52Q9U
537X8
sort
creationdate2012
titleInternational longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
authorKakkar, Ajay K., MBBS, PhD ; Mueller, Iris, MD ; Bassand, Jean-Pierre, MD ; Fitzmaurice, David A., MD ; Goldhaber, Samuel Z., MD ; Goto, Shinya, MD, PhD ; Haas, Sylvia, MD ; Hacke, Werner, MD ; Lip, Gregory Y.H., MD ; Mantovani, Lorenzo G., MD ; Verheugt, Freek W.A., MD ; Jamal, Waheed, MD ; Misselwitz, Frank, MD, PhD ; Rushton-Smith, Sophie, PhD ; Turpie, Alexander G.G., MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1633t-f57f4b7021945e90ab8b69ee6174c68ab651a17a51114a9c30e8d3d0ba9aa56b3
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Abridged Index Medicus
1Anticoagulants
2Anticoagulants (Medicine)
3Anticoagulants - administration & dosage
4Atrial fibrillation
5Atrial Fibrillation - complications
6Atrial Fibrillation - drug therapy
7Atrial Fibrillation - mortality
8Biological and medical sciences
9Blood clots
10Blood. Blood coagulation. Reticuloendothelial system
11Cardiac dysrhythmias
12Cardiology. Vascular system
13Cardiovascular
14Clinical medicine
15Cohort Studies
16Global Health
17Heart
18Humans
19Longitudinal Studies
20Medical sciences
21Multicenter Studies as Topic
22Neurology
23Patient Selection
24Pharmacology. Drug treatments
25Prospective Studies
26Recruitment
27Registries
28Research Design
29Risk Factors
30Stroke
31Stroke (Disease)
32Stroke - complications
33Stroke - drug therapy
34Stroke - mortality
35Vascular diseases and vascular malformations of the nervous system
36Veins & arteries
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Kakkar, Ajay K., MBBS, PhD
1Mueller, Iris, MD
2Bassand, Jean-Pierre, MD
3Fitzmaurice, David A., MD
4Goldhaber, Samuel Z., MD
5Goto, Shinya, MD, PhD
6Haas, Sylvia, MD
7Hacke, Werner, MD
8Lip, Gregory Y.H., MD
9Mantovani, Lorenzo G., MD
10Verheugt, Freek W.A., MD
11Jamal, Waheed, MD
12Misselwitz, Frank, MD, PhD
13Rushton-Smith, Sophie, PhD
14Turpie, Alexander G.G., MD
collection
0NARCIS
1NARCIS: Datasets
2NARCIS:Publications
3Pascal-Francis
4Medline
5MEDLINE
6MEDLINE (Ovid)
7MEDLINE
8MEDLINE
9PubMed
10CrossRef
11Academic OneFile (A&I only)
12ProQuest Central (Corporate)
13Biotechnology Research Abstracts
14Nursing & Allied Health Database
15Physical Education Index
16Health & Medical Collection
17ProQuest Central (purchase pre-March 2016)
18Healthcare Administration Database (Alumni)
19Medical Database (Alumni Edition)
20ProQuest Pharma Collection
21Public Health Database
22Technology Research Database
23Hospital Premium Collection
24Hospital Premium Collection (Alumni Edition)
25ProQuest Central (Alumni) (purchase pre-March 2016)
26Research Library (Alumni Edition)
27ProQuest Central (Alumni Edition)
28British Nursing Database
29ProQuest Central Essentials
30ProQuest Central
31ProQuest Central Korea
32Engineering Research Database
33Health Research Premium Collection
34Health Research Premium Collection (Alumni)
35ProQuest Central Student
36Research Library Prep
37ProQuest Health & Medical Complete (Alumni)
38Nursing & Allied Health Database (Alumni Edition)
39Health & Medical Collection (Alumni Edition)
40Healthcare Administration Database
41Medical Database
42Research Library
43Research Library (Corporate)
44Nursing & Allied Health Premium
45Biotechnology and BioEngineering Abstracts
46Research Library China
47ProQuest One Academic Eastern Edition
48ProQuest One Academic
49ProQuest One Academic UKI Edition
50ProQuest Central China
51ProQuest Central Basic
52MEDLINE - Academic
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Kakkar, Ajay K., MBBS, PhD
1Mueller, Iris, MD
2Bassand, Jean-Pierre, MD
3Fitzmaurice, David A., MD
4Goldhaber, Samuel Z., MD
5Goto, Shinya, MD, PhD
6Haas, Sylvia, MD
7Hacke, Werner, MD
8Lip, Gregory Y.H., MD
9Mantovani, Lorenzo G., MD
10Verheugt, Freek W.A., MD
11Jamal, Waheed, MD
12Misselwitz, Frank, MD, PhD
13Rushton-Smith, Sophie, PhD
14Turpie, Alexander G.G., MD
formatjournal
genrearticle
ristypeJOUR
atitleInternational longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
jtitleThe American heart journal
addtitleAm Heart J
date2012
risdate2012
volume163
issue1
spage13
epage19.e1
pages13-19.e1
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractBackground Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
copNew York, NY
pubElsevier Inc
pmid22172431
doi10.1016/j.ahj.2011.09.011